OUR BLOG
Latest Updates & News
At vero eos et accusamus iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos at dolores molestias excepturi sint occaecati cupiditate.
Phase 2b/3 trial HERALD: CVnCoV SARS-CoV-2 mRNA vaccine CANDIDATE
Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate.
COVIDRIVE welcomes 3 new vaccine companies to the consortium
08/02/2022 – Three new vaccine companies (Moderna, Novavax and Valneva) have joined the COVIDRIVE consortium and officially become COVIDRIVE partners. Moderna, Novavax and Valneva will further contribute to the assessment of the effectiveness of COVID-19 vaccines in Europe to support the region’s public health response and address the vaccine companies’ regulatory obligations.
With the inclusion of these three newcomers, COVIDRIVE, which brings together public institutions, small and medium-sized enterprises and vaccine companies, has a total of 11 partners.
P95 nominated for the Trends Gazelles Flemish Brabant 2022
P95 is one of the nominees for the 2022 edition of Trends Gazelles Flemish Brabant. Trends Gazelles award aims to distinguish the fastest-growing Belgian companies over the past 5 years.
P95 appoints Henk Hoornaert as Chief Commercial Officer
P95 has appointed Henk Hoornaert as Chief Commercial Officer (CCO). After two years of accelerated growth, this appointment will strengthen P95’s structure and improve business development, marking a further step towards a more stable and mature organization.
WHO global vaccine safety multi-country collaboration project on safety in pregnancy
Standardized case definitions strengthen post-marketing safety surveillance of new vaccines by improving generated data, interpretation and comparability across surveillance systems.
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial
We used the RNActive® technology platform (CureVac N.V., Tübingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for a stabilized form of SARS-CoV‑2 spike (S) protein encapsulated in lipid nanoparticles (LNP).
Largest ever Lassa fever study expands to more countries in West Africa
Largest study to provide a more accurate assessment of the incidence of Lassa fever infections expands in West Africa
The COVIDRIVE project officially launches
A new public-private partnership – COVIDRIVE – announced today that it will begin studies to assess the effectiveness...
Controlled Human Infection Studies: Proposals for guidance on how to design, develop and produce a challenge strain
There is an increasing need to establish quality principles for designing, developing and manufacturing challenge agents as currently these agents are classified differently by various jurisdictions.
P95 Acquires Pallas Health Research and Consultancy
It is with great pleasure to announce that P95 has acquired Pallas Health Research and Consultancy. Pallas is an...
Stefaan Castelein Joins P95 as Chief Financial Officer
P95, a service provider specialized in epidemiology, statistics and pharmacovigilance, is happy to announce that...
P95 gives a harmacovigilance training in Beijing
P95 delivers a Pharmacovigilance Course to Asian vaccine manufacturers